NOVAVAX INC(NVAX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

NOVAVAX INC (NVAX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVAX at 18.0/100 on a 32-signal composite quality model, placing it at rank #2,814 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.9) and profitability (9.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NOVAVAX INC reports quarterly revenue of $56.7M, net income of $-53.4M. Top institutional holders of NVAX by reported 13-F value include SHAH CAPITAL MANAGEMENT, BlackRock, STATE STREET, based on the most recent SEC filings. NVAX trades on the Nasdaq exchange and files with the SEC under CIK 1000694. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVAX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NOVAVAX INC directly from SEC EDGAR.